Summary of Key Points Core Viewpoint - The investment and financing landscape of the medical beauty injection materials industry in China is relatively mature, with a significant number of investment events and a focus on scientific research and technology services. Group 1: Financing Status - As of June 2025, there have been 39 investment events in the medical beauty injection materials industry, indicating a mature investment environment [2][4]. - The majority of financing events are concentrated in Shandong and Jiangsu provinces, with Shandong having 8 events and Jiangsu 7 events [4]. Group 2: External Investment Layout - Representative companies in the medical beauty injection materials industry have engaged in numerous external investment events, primarily focusing on scientific research and technology services, which account for approximately 58% of their investments [14][13]. - Other sectors of investment include manufacturing (18%) and wholesale and retail (8%) [14]. Group 3: Mergers and Acquisitions - The level of mergers and acquisitions in the medical beauty injection materials industry is relatively low, with notable participation from real estate companies. For instance, Lushang Development acquired 100% of Shandong Furuida Pharmaceutical Group in 2018 to enter the medical beauty sector [16].

Key Points - The top three stocks with net inflows from southbound funds are Yingfu Fund (02800) with 1.184 billion, Alibaba-W (09988) with 730 million, and Hang Seng China Enterprises (02828) with 556 million [1] - The top three stocks with net outflows are WuXi Biologics (02269) with -539 million, Hua Hong Semiconductor (01347) with -509 million, and SMIC (00981) with -432 million [1] - In terms of net inflow ratio, Shanghai Industrial Holdings (00363) leads with 63.56%, followed by Bank of China Aviation Leasing (02588) with 60.26%, and Sunshine Insurance (06963) with 55.37% [1] - The top three stocks with the highest net outflow ratios are GX China (03040) at -100.00%, Southern Hang Seng Index ETF (03037) at -65.52%, and Sichuan Chengyu Expressway (00107) at -49.23% [1] Top 10 Net Inflows - Yingfu Fund (02800) had a net inflow of 1.184 billion, representing a 16.79% increase, closing at 25.380 [2] - Alibaba-W (09988) saw a net inflow of 730 million, with a 10.34% increase, closing at 116.300 [2] - Hang Seng China Enterprises (02828) had a net inflow of 556 million, with an 8.70% increase, closing at 91.160 [2] - Xiaomi Group-W (01810) had a net inflow of 473 million, with a 6.69% increase, closing at 51.250 [2] - Zai Ding Pharmaceutical (09688) had a net inflow of 429 million, with a 26.73% increase, closing at 27.200 [2] Top 10 Net Outflows - WuXi Biologics (02269) experienced a net outflow of -539 million, with a -33.02% decrease, closing at 29.360 [2] - Hua Hong Semiconductor (01347) had a net outflow of -509 million, with a -21.78% decrease, closing at 44.000 [2] - SMIC (00981) saw a net outflow of -432 million, with a -3.98% decrease, closing at 48.660 [2] - Kuaishou-W (01024) had a net outflow of -292 million, with a -14.76% decrease, closing at 79.150 [2] - Juzi Biotechnology (02367) experienced a net outflow of -220 million, with a -24.75% decrease, closing at 59.000 [2] Net Inflow Ratios - Shanghai Industrial Holdings (00363) had a net inflow ratio of 63.56%, with a net inflow of 11.36 million, closing at 14.870 [3] - Bank of China Aviation Leasing (02588) had a net inflow ratio of 60.26%, with a net inflow of 3.56 million, closing at 73.500 [3] - Sunshine Insurance (06963) had a net inflow ratio of 55.37%, with a net inflow of 2.48 million, closing at 3.790 [3] - Poly Property (06049) had a net inflow ratio of 52.60%, with a net inflow of 1.14 million, closing at 34.880 [3] Net Outflow Ratios - GX China (03040) had a net outflow ratio of -100.00%, with a net outflow of -7100.00, closing at 35.460 [3] - Southern Hang Seng Index ETF (03037) had a net outflow ratio of -65.52%, with a net outflow of -724,900, closing at 25.400 [3] - Sichuan Chengyu Expressway (00107) had a net outflow ratio of -49.23%, with a net outflow of -380,740, closing at 4.920 [3]

格隆汇8月12日丨巨子生物(02367.HK)公告，谨定于2025年8月27日(星期三)举行董事会会议，以考虑及 通过集团截至2025年6月30日止6个月中期业绩，及派发中期股息(如有)，以及处理其他事项。 ...

（於 開 曼 群 島 註 冊 成 立 的 獲 豁 免 有 限 公 司） （股 份 代 號：2367） 董事會會議召開日期 巨子生物控股有限公司（「本公司」及 其 附 屬 公 司「本集團」）董事會（「董事會」）兹 通告謹定於2025年8月27日（星 期 三）舉 行 董 事 會 會 議，以 考 慮 及 通 過 本 集 團 截 至 2025年6月30日 止 六 個 月 之 中 期 業 績，及 派 發 中 期 股 息（如 有），以 及 處 理 其 他 事 項。 承董事會命 巨子生物控股有限公司 董事會主席 GIANT BIOGENE HOLDING CO., LTD 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 巨子生物控股有限公司 嚴建亞 中 國 西 安，2025年8月12日 截至本公告日期，董事會成員包括執行董事嚴建亞先生、葉娟女士、方娟女士、 張 慧 娟 女 士 及 嚴 鈺 博 女 士 以 及 ...

Core Viewpoint - The company acknowledges limitations in its current testing methods for recombinant collagen products and outlines steps for improvement in response to industry and consumer demands [1][2]. Group 1: Company Response - The company has conducted a comprehensive self-inspection of its recombinant collagen raw materials and products, including production, testing, and labeling [1]. - It plans to collaborate with research institutions to optimize and validate qualitative and quantitative testing methods for recombinant collagen in cosmetics [1]. - The company will gradually disclose key technical parameters and quality control data for raw materials and finished products to enhance industry development and public oversight [1]. Group 2: Industry Standards and Practices - The company adheres to existing industry standards and has established its own quality control measures for raw materials and products [2]. - It is actively participating in the formulation of national and industry standards related to recombinant collagen in cosmetics to promote standardized development within the industry [1][2]. Group 3: Company Background and Market Performance - Founded in 2000, the company was listed on the Hong Kong Stock Exchange in 2022 and specializes in skin care products featuring recombinant collagen as a key active ingredient [2]. - The company's stock price has experienced significant fluctuations, with a decline of 37.12% from its peak of 87.1 HKD per share on May 20, 2025, to June 23, 2025 [2]. - Following the recent announcement, the stock price rose by 6.74% to 54.65 HKD per share as of June 24, 2025 [2].

智通财经APP获悉，根据2025年8月11日披露数据，中国电信（00728）、绿色动力环保（01330）、中 国神华（01088）位居港股通持股比例前3位，分别为74.59%、69.90%、68.25%。此外，腾讯控股 （00700）、阿里巴巴－W（09988）、小米集团－Ｗ（01810）在最近有统计数据的5个交易日内，持股 额增幅最大，分别为+27.57亿元、+18.94亿元、+16.98亿元;中国移动（00941）、泡泡玛特（09992）、 巨子生物（02367）在最近有统计数据的5个交易日内，持股额减幅最大，分别为-12.99亿元、-4.36亿 元、-3.77亿元。 具体数据如下（交易所数据根据T+2日结算）： | 公司名称 | 持股额变动 | 持股数变动 | | --- | --- | --- | | 腾讯控股(00700) | +27.57亿元 | +491.40万股 | | 阿里巴巴－W(09988) | +18.94亿元 | +1597.98万股 | | 小米集团－Ｗ(01810) | +16.98亿元 | +3342.22万股 | | 盈富基金(02800) | +14.00亿元 | +551 ...

Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 74.70%, Green Power Environmental (01330) at 70.03%, and China Shenhua (01088) at 68.18% [1] - Tencent Holdings (00700), Alibaba-W (09988), and Kuaishou-W (01024) saw the largest increases in holding amounts over the last five trading days, with increases of +2.39 billion, +2.11 billion, and +1.60 billion respectively [1] - The largest decreases in holding amounts over the last five trading days were recorded by the Tracker Fund of Hong Kong (02800) at -7.82 billion, Hang Seng China Enterprises (02828) at -4.88 billion, and China Mobile (00941) at -1.34 billion [1] Hong Kong Stock Connect Latest Holding Ratios - China Telecom (00728): 10.368 billion shares, 74.70% holding ratio [1] - Green Power Environmental (01330): 0.283 billion shares, 70.03% holding ratio [1] - China Shenhua (01088): 2.303 billion shares, 68.18% holding ratio [1] - Other notable companies include Tianjin Chuangye Environmental (01065) at 64.43% and New天绿色能源 (00956) at 63.76% [1] Recent Increases in Holdings (Last 5 Trading Days) - Tencent Holdings (00700): +2.39 billion, +4.2595 million shares [1] - Alibaba-W (09988): +2.11 billion, +18.1194 million shares [1] - Kuaishou-W (01024): +1.60 billion, +20.1638 million shares [1] - Other companies with significant increases include China Shenhua (01088) and China Life (02628) [1] Recent Decreases in Holdings (Last 5 Trading Days) - Tracker Fund of Hong Kong (02800): -7.82 billion, -30.82404 million shares [1] - Hang Seng China Enterprises (02828): -4.88 billion, -5.35312 million shares [1] - China Mobile (00941): -1.34 billion, -1.54265 million shares [1] - Other companies with notable decreases include Southbound Hang Seng Technology (03033) and Guotai Junan International (01788) [1]

Core Insights - The functional skincare industry in China is experiencing a rise of domestic brands, with a focus on products that address specific skin issues and provide therapeutic benefits [1][8] - The market size for functional skincare products is projected to exceed 480 billion yuan by 2024, driven by increasing consumer demand for safety and efficacy [25][31] Industry Overview - Functional skincare products are defined as cosmetics or medical devices that target specific skin problems and possess pharmacological effects [1] - The industry is currently in a phase of domestic brand emergence, with significant growth in market share for local brands like Winona and Huaxi Biological [8] Industry Chain Analysis - The functional skincare industry chain consists of upstream raw material suppliers, midstream manufacturers, and downstream sales channels [4][6] - Key raw materials include collagen, hyaluronic acid, and peptides, while packaging materials range from paper to glass [4] Market Development History - The industry has gone through three stages: initiation (1998-2008), transformation (2009-2014), and the current rise of domestic brands (2015-present) [8] - The entry of brands like Vichy and Avene marked the beginning of the functional skincare market in China [8] Policy Background - The industry is governed by regulations applicable to both cosmetics and medical devices, focusing on efficacy claims and labeling management [11][13] Current Market Status - The market is characterized by three main segments: dermatological skincare, high-efficacy skincare, and medical-grade skincare [14] - Consumers are increasingly focused on product efficacy, safety, and ingredient transparency, particularly for sensitive skin [15][16] Sales Channels - Online sales channels dominate the market, with companies like Proya achieving significant revenue from e-commerce [20] - The sales strategy often includes a combination of online and offline channels to maximize reach [19] Profitability - The gross profit margins for most listed companies in the functional skincare sector exceed 70%, with some companies like Jinbo Biological reaching 92.02% due to their focus on medical devices [24] Market Size and Growth - The functional skincare market in China has grown from 10.25 billion yuan in 2017 to an estimated 48.743 billion yuan in 2024 [25][28] - The market is expected to reach 86 billion yuan by 2030, with a compound annual growth rate of approximately 9.0% [33] Competitive Landscape - The competitive landscape is led by companies like Betaini, which holds an 11.71% market share, followed by Huaxi Biological and others [31] - The industry is concentrated in coastal regions, particularly Shanghai and Guangdong [28] Future Trends - The penetration rate of functional skincare products is expected to increase, with a focus on product innovation and medical endorsements [35] - The industry is likely to see intensified competition as consumer preferences evolve towards more personalized and effective solutions [33]

Investment Rating - The report suggests a focus on companies in the recombinant collagen sector, highlighting their potential for growth and market leadership [5][6]. Core Insights - Collagen is essential for human health, providing structural support and biological functions [11][14]. - The domestic recombinant collagen technology is advanced, with a complete industrial chain and supportive policies driving growth [6][31]. - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen [6][27]. - The applications of collagen are diverse, including medical aesthetics, skincare, intimate health, and hair health [6][33]. Summary by Sections 1. Collagen as a Vital Component - Collagen constitutes 30%-40% of human protein and is crucial for skin, bones, tendons, and ligaments [11][14]. - There are at least 29 types of collagen in the human body, with types I and III being the most common in the skin [14][15]. 2. Production: Recombinant vs. Animal-Derived Collagen - Recombinant collagen is produced using gene engineering, offering advantages such as no virus risk and better biocompatibility compared to animal-derived collagen [19][26]. - The market for recombinant collagen is expected to reach 286.3 billion yuan in 2023, with a significant growth trajectory [27][28]. 3. Policy Support for Market Development - The regulatory framework for recombinant collagen has been improving, with various guidelines issued since 2021 to standardize the industry [31][32]. 4. Diverse Applications of Recombinant Collagen - **Medical Aesthetics**: The market for recombinant collagen in medical aesthetics is projected to grow from 43 billion yuan in 2023 to 143 billion yuan by 2027, with a CAGR of 35.4% [6][42]. - **Skincare**: The market for functional skincare products containing recombinant collagen is expected to grow from 115 billion yuan in 2023 to 665 billion yuan by 2027, with a CAGR of 54.9% [47][49]. - **Intimate Health**: The market for intimate health products is anticipated to grow significantly, driven by increasing consumer awareness and demand [51][52]. 5. Key Companies in the Industry - **Jinbo Biological**: A leader in recombinant collagen with unique medical aesthetic products [5][40]. - **Juzi Biological**: Known for its brands Kefu Mei and Keli Jin, actively expanding its medical aesthetic pipeline [5][40]. - **Marubi Biological**: Accelerating its research in collagen, with significant product launches [5][40].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 巨子生物控股有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額 ...